Viking Therapeutics, Inc. (VKTX) stock
VKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$26.17−0.71 (-2.64%)
Close on Nov 18, 2026Market cap $3.34BP/E –Yield –
Viking Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Viking Therapeutics's operating income for the twelve months ending Sep 30, 2026 was -$648.57M. For fiscal 2025 it was -$393.34M. The highest annual figure on record is -$12.00M in fiscal 2015.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$393.34M | – |
| FY2024 | Dec 31, 2024 | -$150.92M | – |
| FY2023 | Dec 31, 2023 | -$100.83M | – |
| FY2022 | Dec 31, 2022 | -$70.36M | – |
| FY2021 | Dec 31, 2021 | -$55.68M | – |
| FY2020 | Dec 31, 2020 | -$42.66M | – |
| FY2019 | Dec 31, 2019 | -$32.69M | – |
| FY2018 | Dec 31, 2018 | -$26.16M | – |
| FY2017 | Dec 31, 2017 | -$19.07M | – |
| FY2016 | Dec 31, 2016 | -$13.85M | – |
| FY2015 | Dec 31, 2015 | -$12.00M | – |
| FY2014 | Dec 31, 2014 | -$23.47M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$187.11M | – |
| Q2 FY2026 | Jun 30, 2026 | -$132.60M | – |
| Q1 FY2026 | Mar 31, 2026 | -$164.13M | – |
| Q4 FY2025 | Dec 31, 2025 | -$164.74M | – |
| Q3 FY2025 | Sep 30, 2025 | -$98.56M | – |
| Q2 FY2025 | Jun 30, 2025 | -$74.57M | – |
| Q1 FY2025 | Mar 31, 2025 | -$55.47M | – |
| Q4 FY2024 | Dec 31, 2024 | -$46.24M | – |
| Q3 FY2024 | Sep 30, 2024 | -$36.56M | – |
| Q2 FY2024 | Jun 30, 2024 | -$34.05M | – |
| Q1 FY2024 | Mar 31, 2024 | -$34.07M | – |
| Q4 FY2023 | Dec 31, 2023 | -$29.29M | – |
| Q3 FY2023 | Sep 30, 2023 | -$27.27M | – |
| Q2 FY2023 | Jun 30, 2023 | -$23.74M | – |
| Q1 FY2023 | Mar 31, 2023 | -$20.54M | – |
| Q4 FY2022 | Dec 31, 2022 | -$20.28M | – |
| Q3 FY2022 | Sep 30, 2022 | -$16.20M | – |
| Q2 FY2022 | Jun 30, 2022 | -$17.63M | – |
| Q1 FY2022 | Mar 31, 2022 | -$16.25M | – |
| Q4 FY2021 | Dec 31, 2021 | -$12.51M | – |
| Q3 FY2021 | Sep 30, 2021 | -$13.40M | – |
| Q2 FY2021 | Jun 30, 2021 | -$15.54M | – |
| Q1 FY2021 | Mar 31, 2021 | -$14.23M | – |
| Q4 FY2020 | Dec 31, 2020 | -$11.27M | – |
| Q3 FY2020 | Sep 30, 2020 | -$9.84M | – |
| Q2 FY2020 | Jun 30, 2020 | -$10.61M | – |
| Q1 FY2020 | Mar 31, 2020 | -$10.95M | – |
| Q4 FY2019 | Dec 31, 2019 | -$8.87M | – |
| Q3 FY2019 | Sep 30, 2019 | -$7.44M | – |
| Q2 FY2019 | Jun 30, 2019 | -$9.57M | – |
| Q1 FY2019 | Mar 31, 2019 | -$6.81M | – |
| Q4 FY2018 | Dec 31, 2018 | -$7.04M | – |
| Q3 FY2018 | Sep 30, 2018 | -$7.39M | – |
| Q2 FY2018 | Jun 30, 2018 | -$6.93M | – |
| Q1 FY2018 | Mar 31, 2018 | -$4.81M | – |
| Q4 FY2017 | Dec 31, 2017 | -$4.43M | – |
| Q3 FY2017 | Sep 30, 2017 | -$4.69M | – |
| Q2 FY2017 | Jun 30, 2017 | -$4.98M | – |
| Q1 FY2017 | Mar 31, 2017 | -$4.97M | – |
| Q4 FY2016 | Dec 31, 2016 | -$3.74M | – |
See a number that looks wrong?